Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Marker Distinguishes More-Aggressive From Less-Aggressive Forms Of Chronic Leukemia

People newly diagnosed with chronic leukemia must often wait to learn if they have a faster- or slower-progressing form of the disease.

This study identified a molecular marker that quickly helps to distinguish which form a patients has.

The findings could enable patients with aggressive disease to start treatment sooner.

Researchers have identified a prognostic marker in the most common form of chronic leukemia that can help to distinguish which patients should start treatment quickly from those who can safely delay treatment, perhaps for years.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), focused on chronic lymphocytic leukemia (CLL), a malignancy expected to occur in 16,000 Americans this year and cause 4,600 deaths.

The researchers examined a gene called ZAP-70 in CLL cells for a chemical change called methylation. They found that when the gene in leukemia cells is methylated, patients are likely to have the slow-progressing form of CLL, and when the ZAP-70 gene is unmethylated, patients are likely to have aggressive disease and should consider beginning treatment immediately.

Currently, doctors must simply observe newly diagnosed patients to determine which type of CLL they have. This can delay the start of treatment in patients with aggressive disease, or it can lead to treating patients who don’t yet require it.

The findings are published in the Journal of Clinical Oncology.

“This study demonstrates that ZAP-70 methylation status is a highly predictive, reproducible biomarker of poor prognosis in this disease, and a clinically useful prognostic test for CLL,” says principal investigator Dr. John Byrd, a CLL specialist and professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences at the OSUCCC – James.

Currently, the presence of mutations in a gene called IGVH (immunoglobulin heavy chain variable region gene), and the amount of protein produced by the ZAP-70 gene in CLL cells are sometimes used to predict prognosis and response to treatment in people with this disease, “but these assays are expensive and difficult to perform,” says coauthor and researcher Dr. David Lucas, research assistant professor and CLL specialist at the OSUCCC – James.

“In all cells, some areas of DNA undergo methylation, which controls how that DNA is used,” Lucas says. “In cancer cells, the pattern of DNA methylation is often different from that of healthy cells, and this influences how much protein is produced by ZAP-70 and other genes.”

Because the protein produced by the ZAP-70 gene is often present at different levels in leukemia cells, Byrd, Lucas and their colleagues hypothesized that changes in ZAP-70 methylation status could explain decreases in the gene’s expression and a more favorable clinical outcome.

The researchers examined CLL cells from 247 patients obtained through four independent clinical trials. Project co-leader, Dr. Christoph Plass, of the Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center in Heidelberg, Germany, used a new mass spectroscopy-based technique to assess DNA methylation of the ZAP-70 regulatory region.

Funding from the German Research Society, NIH/National Cancer Institute (grants CA101956, CA140158, CA95426, CA81534, 1K12CA133250), The Leukemia & Lymphoma Society, The Harry Mangurian Foundation, and The D. Warren Brown Foundation supported this research.

Other researchers involved in this study were Amy S. Ruppert, Lianbo Yu, Nyla A. Heerema and Guido Marcucci of Ohio State University; Rainer Claus, Manuela Zucknick and Christopher C. Oakes of the German Cancer Research Center, Heidelberg; Stephan Stilgenbauer, Daniel Mertens, Andreas Bühler and Hartmut Döhner of the University of Ulm, Germany; Richard A. Larson of the University of Chicago; Neil E. Kay and Diane F. Jelinek of Mayo Clinic; Thomas J. Kipps and Laura Z. Rassenti of the University of California, San Diego; and John G. Gribben of the University of London, United Kingdom.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S.News & World Report.

Contact: Darrell E. Ward, Medical Center Public Affairs and Media Relations,
614-293-3737, or

Darrell E. Ward | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

TRAPPIST-1 planets provide clues to the nature of habitable worlds

21.03.2018 | Physics and Astronomy

The search for dark matter widens

21.03.2018 | Materials Sciences

Natural enemies reduce pesticide use

21.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>